Open AccessShould Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?
Author(s) -
Samuel L Aitken,
Farnaz Foolad,
Patrick M. McDaneld
Publication year - 2017
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01160-17
Subject(s) - piperacillin/tazobactam , enterobacteriaceae , piperacillin , bacteremia , microbiology and biotechnology , tazobactam , medicine , biology , antibiotics , bacteria , escherichia coli , gene , antibiotic resistance , pseudomonas aeruginosa , genetics , imipenem
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom